

Understanding Influences on the Use of Professional Practice Guidelines by Pharmacists: A Qualitative Application of the COM-B Model of Behaviour

Investigators

Authors: *Deanna Mill¹ Dr Liza Seubert¹ Dr Kenneth Lee¹ Dr Amy Page^{1,2,3} Dr Jacinta Johnson^{4,5} Dr Sandra Salter¹ Prof Rhonda Clifford¹ Emma Murace¹ Fraser Fullerton¹ Matthew D. Halliday¹ Altinka Res¹ Dr Danielle D'Lima⁶

Author Affiliations and/or Institution where work was carried out:

1. School of Allied Health, University of Western Australia
2. Pharmacy Department, The Alfred
3. Centre for Medicines Use and Safety, Monash University
4. UniSA Clinical and Health Sciences, University of South Australia
5. SA Pharmacy, SA Health, Adelaide, Australia
6. Centre for Behaviour Change, Department of Clinical, Educational and Health Psychology, University College London

Corresponding author:

Ms Deanna Mill

Deanna.Mill@research.uwa.edu.au

Declarations

Ethics approval and consent to participate:

Ethics approval has been received from UWA HREC: RA/4/20/6014. Participants provided informed consent.

Availability of data and materials:

The datasets used and/or analysed during the current study may be available from the corresponding author conditionally in line with appropriate ethical approval.

Competing interests:

At the time of writing this manuscript Deanna Mill was appointed as a Board Director for the Pharmaceutical Society of Australia. Employees of the Pharmaceutical Society of Australia reviewed the content of the discussion guide and advertised the opportunity to participate in the study. They did not have any other involvement in the study design; data collection, analyses and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Funding:

This study was partially funded by the Pharmaceutical Society of Australia.

Authors contributions:

Deanna Mill: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Visualization, Writing - original draft, Writing - review & editing. Emma Murace: Data curation, Formal analysis. Matthew Halliday: Data curation, Formal analysis. Fraser Fullerton: Data curation, Formal analysis. Altinka Res: Data Curation, Formal Analysis. Jacinta L Johnson: Supervision, Writing - review & editing. Kenneth Lee: Supervision, Writing - review & editing. Sandra M Salter: Supervision, Writing - review & editing. Danielle D'Lima: Supervision, Writing - review & editing. Liza Seubert: Supervision Writing - review & editing. Rhonda Clifford: Funding acquisition, Supervision, Writing - review & editing. Amy Page: Supervision, Writing - review & editing.

Acknowledgements:

The authors would like to thank the focus group participants for sharing their perspectives. The authors also thank Master of Pharmacy students at the University of Western Australia who assisted with piloting and pretesting. The authors thank Diana Benino (DB) for her assistance with recruitment and data collection. The authors also thank members of the Pharmaceutical Society of Australia's project team and the Enhancing Quality in Pharmacy Practice (EQiPP) project expert advisory group for their input into recruitment strategies and discussion guide content. DM is supported by an Australian Government Research Training Program Scholarship at The University of Western Australia. AP is supported by an NHMRC Early Career Fellowship (1156892).

Abstract

Background: Pharmacy practice in Australia is guided by professional practice guidelines. The guidelines communicate expected pharmacist behaviours to facilitate a consistently high standard of patient care, but are infrequently used by pharmacists and students. It is therefore essential to understand what influences pharmacists' use of professional practice guidelines and how best to support positive behaviour change towards utilising these guidelines.

Objective: To explore perceived influences on the use of professional practice guidelines by Australian pharmacists, and to map these influences to the COM-B model of behaviour.

Method: Focus group discussions were undertaken with pharmacists (including intern pharmacists) from various practice settings, locations, and with varying years of experience. Audio-recordings from each focus group were de-identified and transcribed verbatim. Transcripts were analysed using the COM-B ('capability', 'opportunity', 'motivation' and 'behaviour') model.

Results: Nine focus groups with 45 participants were conducted. Limited awareness of professional practice guidelines hindered pharmacists' 'capability' to use them. Pharmacists indicated that challenges accessing, and suboptimal content design, limited their 'opportunity' to use the guidelines. Pharmacists' professional role and identity ('motivation') appeared to inhibit use of the guidelines if they were perceived to not apply to their current role, or if pharmacists believed their experience obviated the need to use them. Motivation to use professional practice guidelines was associated with a belief that the guideline(s) would support pharmacists in their practice.

Conclusion(s): Understanding what influences the use of professional practice guidelines should inform interventions to target and improve pharmacists' use of the guidelines. The Behaviour Change Wheel offers clear next steps for this process. Awareness, access, and content could be improved in the first instance, and this may also work to improve motivation. Leveraging influences on motivation may serve to ensure that use of professional practice guidelines is embedded in future practice, albeit motivation can be more difficult to target.

Keywords

Pharmacist, guidelines, behaviour change, professional practice

List of abbreviations

PSA = Pharmaceutical Society of Australia

BCW = Behaviour Change Wheel

COM-B = Capability, Opportunity, Motivation-Behaviour

APF = Australian Pharmaceutical Formulary and Handbook

1 Introduction

2 For numerous years the International Pharmaceutical Federation has tasked their member organisations with
3 ensuring each country has quality guidelines and standards in place for the provision of 'Good Pharmacy Practice'.^{1,2}
4 Australia is one country where professional practice resources, particularly professional practice guidelines are
5 readily available. The Pharmaceutical Society of Australia has been the custodian of these guidelines for over a
6 decade.³⁻⁵ While the scope and purpose of these guidelines may differ, they all communicate to pharmacists the
7 minimum expectation of quality pharmacist practice, that is a key component of meeting legal, ethical and
8 professional obligations.³⁻⁵ Of these, arguably the most important are those from regulators and professional bodies
9 that provide guidance for pharmacists on the minimum expectation for care provided to patients.³⁻⁶ Such guidelines
10 may include, but are not limited to, codes of ethics, codes of conduct, professional practice standards, service
11 specific practice guidelines, medicine formularies, and medicine specific provision guidelines.^{3-5,7-9} These guidelines
12 range in their scope and purpose, but all function to educate pharmacists to enable consistent, evidenced based,
13 safe, and effective service provision to patients.

14
15 When pharmacists are accused of malpractice the related professional practice guidelines are often viewed to bench
16 mark their practice.^{4,10,11} Beyond this, adhering to practice guidelines ensures pharmacists are not in breach of
17 funding service agreements, meet agreed expectations of consumers and other health professionals, and are able to
18 self-assess the quality of their own practice.^{3,4,6,10} Furthermore, these guidelines can clarify how to proceed in
19 unfamiliar situations and assist pharmacists to avoid practice misdemeanours.

20
21 Suboptimal practice in conflict with the expectations outlined in practice guidelines has been observed in pharmacy
22 practice in Australia and overseas, in published and unpublished literature.¹²⁻²⁵ Like all health professions, challenges
23 often arise with consistency of practice where autonomous professionals, including pharmacists, are practicing.
24 These range from illegal practice to substandard provision of information to patients when they purchase a
25 medicine.¹¹ There are a multitude of factors that likely influence suboptimal practice ranging from the individual
26 practitioners' personal capabilities, including their knowledge and training, external factors influencing their practice
27 environment such as access to resources or limited time, and the individuals' motivations including their beliefs and
28 habits.¹¹ One potential explanation for practice deviations from expected professional behaviour may be that the
29 profession's relevant practice guidelines are not known or used optimally.²⁶

30
31 A recent national survey of Australian pharmacists, intern pharmacists and pharmacy students found that almost all
32 (15/16) of the practice guidelines explored were self-reported to be used by less than half of all participants in the
33 preceding 12 months.²⁶ From the pre-defined options in the survey the most reported reasons for not using the
34 practice guidelines included limited awareness, the perception that the information in the guidelines was not
35 needed and lack of relevance to the pharmacist's role.²⁶ Thus, while this study served to demystify the questions of
36 'if' and 'by whom' professional practice guidelines are used, the question remains: what specifically influences
37 pharmacists to use or not use these guidelines? Limited research exploring pharmacists' reasons for use of practice
38 guidelines exists. Of the observational studies comparing pharmacist practice to treatment and medicines provision
39 guidelines, multiple found that a lack of awareness and limited access to the relevant guidelines posed a barrier to
40 them being used and served as one of the reasons for participants deviation from behaviour detailed in the
41 guidelines.^{18,19,23,27} Older studies seeking to understand Australian pharmacists' navigation of ethical problems in
42 practice and dispensing processes similarly called into question the useability of these guidelines in real world
43 practice, citing poor awareness, length, and content as problematic.^{16,28} However, given the primary aim of these
44 studies was to assess practice, rather than reasons for/for not using practice guidelines, the reported insights on
45 these influences have been limited to those listed.


46
47 A comprehensive understanding of what influences the use of pharmacists professional practice guidelines is critical
48 for regulators, professional organisations, guideline writers and the profession itself to ensure these guidelines are
49 fit for purpose and support the provision of quality pharmacist care as intended. Conceptualising the use of practice
50 guidelines as a behaviour, subject to its own influences, may aid in providing further insights into use of these
51 guidelines to achieve this. The capability, opportunity, motivation (COM), behaviour (B) model, also known as COM-B
52 model of behaviour, facilitates the exploration of a behaviour and its influences in the context in which it occurs.^{29,30}
53 For example, the use of professional practice guidelines by pharmacists in their workplace. This model suggests that
54 an individual needs the physical and psychological capability, physical and social opportunity and reflective and

55 automatic motivation for a behaviour to occur.^{29,30} The model proposes these components are part of an interacting
 56 system for a given behaviour (Figure 1). For example, providing a guideline directly to a pharmacist will increase their
 57 physical opportunity to read and use it, which may in turn increase their motivation to do so. Mapping influences to
 58 components of the COM-B model has been extensively applied by researchers and practitioners internationally as an
 59 early step in the Behaviour Change Wheel (BCW) intervention development method (Figure 2). Recent pharmacy
 60 specific examples include, but are not limited to, exploring deprescribing opportunities for community pharmacists
 61 and understanding influences on pharmacy supply of naloxone.^{31,32} The BCW provides a systematic and theory-
 62 informed method for developing behaviour change interventions (Figure 3).^{29,30} It provides practical steps to link the
 63 identification and specification of a behaviour to the assessment of influences on the behaviour.^{29,30} Further steps in
 64 the method involve identifying congruent intervention strategies/components that can inform the design and
 65 evaluation of an intervention (Figure 2).²⁹ This method has been used to successfully design and pilot an intervention
 66 in Australian pharmacy to influence consumers' willingness to speak to pharmacy staff when purchasing over-the-
 67 counter medicines.³³

68 To the researcher's knowledge there has been no work to conceptualise pharmacists' use of professional practice
 69 guidelines as a behaviour, or to openly investigate what influences use of these guidelines. To assist the
 70 development of tailored interventions to optimise the use of professional practice guidelines, a richer understanding
 71 of what influences the use of professional practice guidelines is necessary. The specific aim of this study was to
 72 explore perceived influences on the use of professional practice guidelines by Australian pharmacists, and to map
 73 these influences to the COM-B model of behaviour. This study is part of a broader body of research looking at how
 74 the professionalism, specifically professional behaviour, of Australian pharmacists can be enhanced.
 75


76

The COM-B Model




77

78 **Figure 1 – COM-B Model of Behaviour**²⁹



79

80 **Figure 2 – Behaviour change intervention design process**²⁹



31
32 **Figure 3 – Behaviour Change Wheel** ²⁹

33
34
35 **Methods**

36 **Study design**

37 A descriptive qualitative methodology employing a series of online focus group discussions was undertaken to elicit
38 an in-depth understanding of what influences pharmacists and intern pharmacists to use or not use professional
39 practice guidelines. The professional practice guidelines included in this study were selected in collaboration with
40 the peak body representing Australian pharmacists, the Pharmaceutical Society of Australia (PSA). These included
41 service specific practice guidelines, Code of Ethics, Professional Practice Standards for Pharmacists, medicines supply
42 guidelines and the guidelines in the Australian Pharmaceutical Formulary and Handbook (APF) (Box 1). All of these
43 resources are freely available to all pharmacists, except the guidelines for provision of a Pharmacist Only medicine
44 that can only be accessed by PSA members or those with an APF, which is a mandatory text for dispensing and
45 patient facing pharmacists.³⁴ This study was conducted online in August - September 2020. Given the COVID-19
46 pandemic and physical restrictions in place in Australia at the time of this study, the entire methodology from
47 recruitment to facilitating discussion to reimbursement was conducted completely online. Details on this online
48 method have been published elsewhere.³⁵ The study is reported in line with the Consolidated Criteria for Reporting
49 Qualitative Research (COREQ) checklist (Appendix 1).³⁶

50
51 **Box 1-** Pharmaceutical Society of Australia professional practice guidelines considered

| |
|--|
| Professional practice guidelines considered |
|--|

My Health Record Guidelines for Pharmacists³⁷
 Clinical Governance Principles for Pharmacy Services³⁸
 Dispensing Practice Guidelines¹⁰
 Code of Ethics for Pharmacists⁵
 Professional Practice Standards for Pharmacists⁴
 Guide to Providing Pharmacy Services to Aboriginal and Torres Strait Islander People³⁹
 Guidelines for Pharmacists Providing Dose Administration Aid Services⁸
 Guidelines for Pharmacists Providing Staged Supply Services⁴⁰
 Guidelines for Pharmacists Providing Medscheck and Diabetes Medscheck Services⁴¹
 Practice Guidelines for the Provision of Immunisation Services Within Pharmacy⁴²
 Guidelines for the Continued Dispensing of Eligible Prescribed Medicines by Pharmacists⁴³
 Guidelines for Quality Use of Medicines (QUM) Services⁴⁴
 Guidelines for Pharmacists Providing Home Medicines Review (HMR) Services⁴⁵
 Guidelines for Pharmacists Providing Residential Medication Management Review and QUM Services⁴⁶
 Guidelines for Comprehensive Medication Management Reviews⁴⁷
 *Guidance for provision of a Pharmacist Only medicine Chloramphenicol for ophthalmic use⁴⁸
 *Guidance for provision of a Pharmacist Only medicine-Emergency contraception⁹
 *Guidance for provision of a Pharmacist Only medicine Naloxone⁴⁹
 *Guidance for provision of a Pharmacist Only medicine Orlistat⁵⁰
 *Guidance for provision of a Pharmacist Only medicine Prochlorperazine⁵¹
 *Guidance for provision of a Pharmacist Only medicine Proton pump inhibitors⁵²
 *Guidance for provision of a Pharmacist Only medicine Short-acting beta2-agonists (salbutamol and terbutaline)⁵³
 *Guidance for provision of a Pharmacist Only medicine Famciclovir⁵⁴
 *Guidance for provision of a Pharmacist Only medicine Adrenaline (epinephrine)⁵⁵
 *Guidance for provision of a Pharmacist Only medicine Astodimer sodium⁵⁶
 *Guidance for provision of a Pharmacist Only medicine Glucagon⁵⁷
 *Guidance for provision of a Pharmacist Only medicine High-concentration fluoride toothpaste⁵⁸
 *Guidance for provision of a Pharmacist Only medicine Nitrates⁵⁹
 Guidelines in the Australian Pharmaceutical Formulary and Handbook (APF)⁷

*Guidelines are member only or available in the APF

32
33

34 Ethics approval

35 Approval for the conduct of this study was obtained from the Human Research Ethics Office at the University of
 36 Western Australia (RA/4/20/6014).

37

38 Participants

39 Pharmacists from a range of practice settings, roles and with differing years of experience were recruited to reflect
 40 the diversity within the profession.

41

Eligibility criteria included:

42

1. Australian Health Practitioner Regulation Agency registration as a pharmacist or intern pharmacist.

43

2. Located in Australia.

44

3. Able to provide informed consent to participate.

45

4. Able to access a stable internet connection and participate in discussions via the online videoconference
 46 platform.

47

17 Recruitment and sample

18 Participants were identified and invited to participate in the study through email invitations shared through the
 19 research team's professional networks. Professional bodies such as the PSA, the Pharmacy Guild of Australia and the
 20 Society of Hospital Pharmacists of Australia featured study advertisements in their e-newsletters to pharmacist
 21 members. Social media advertisements were also posted on several platforms (Twitter, Facebook, LinkedIn) and
 22 pharmacist specific forums (PSA Early Career Pharmacist Facebook group). Advertisements included a description of
 23 the study and a link to an online form for interested participants to submit an expression of interest and demographic
 24 details. Participant expressions of interest were reviewed, and participants were invited to participate if they met the
 25 eligibility criteria and were available at scheduled discussion times to enable 4-10 participants for each group. Eligible
 26 participants were selected through purposive sampling to ensure maximum variation in location, practice experience
 27 and demographics was obtained. Participant groups were organised according to current practice role (hospital

28 pharmacists, community pharmacists, pharmacy owners and speciality practice pharmacists) to minimise response
29 bias and increase synergy within groups. Participants were provided with a \$60 online retail gift card for participation.
30

31 Research team

32 LS is a pharmacist and academic with extensive experience in employing focus group methodology to acquire
33 insights into pharmacy practice and is an experienced focus group moderator. KL is a pharmacist and academic with
34 extensive experience in qualitative methodology. In particular, KL has considerable experience in focus group design
35 and qualitative analysis methods. DD is an academic with a background in professional behaviour change. She has
36 extensive experience in applying behaviour change theories, models and frameworks using qualitative research
37 methods.
38

39 Researcher training

40 Both LS and KL conducted training for DM and the support researchers responsible for assisting in focus group
41 facilitation (MH, AR, FF, EM, JJ). Training was in the form of extensive discussion about research topic and aims,
42 information about focus group facilitation and observation of LS conducting a pilot focus group. DM then conducted
43 a pilot focus group under observation of LS and KL with targeted feedback on technique provided. KL also conducted
44 training on coding and thematic analysis using frameworks for DM, FF and EM. This involved discussion of different
45 coding techniques using an inductive or deductive approach and feedback provided on coding of pilot transcripts.
46

47 Discussion guide

48 The interview guide was developed by members of the research team with input from the Pharmaceutical Society of
49 Australia project team and members of an expert advisory group. Development of open-ended questions to explore
50 participant view, specific prompts covering each component of the COM-B model were discussed, reviewed and
51 finalised by the team. The expert advisory group consisted of representatives from professional pharmacist
52 organisations and experienced pharmacy practice researchers, all with extensive experience practising as
53 pharmacists and/or developing professional practice guidelines. The discussion guide probed participants about their
54 perceptions on the barriers and facilitators to the use of professional practice guidelines (see Table 1). The section
55 covered a general discussion of the use of professional practice guidelines, followed by more specific questions
56 about barriers and facilitators to their use. Question probes were guided by the COM-B model of behaviour to
57 ensure all potential influences were explored (Table 1).²⁹ A presentation featuring the professional practice
58 guidelines and discussion questions was also shared to aid participants in answering questions.
59

60 **Table 1** – Discussion themes, questions and prompts based on COM-B for focus group discussion on influences on
61 use of professional practice guidelines
62

| Participant group: Pharmacists (community, hospital, owners) | |
|--|---------|
| Discussion theme | Prompts |

| | |
|---|--|
| <p>Please describe a situation where you have used (or have seen someone else use) a professional practice guideline?</p> <p>The PSA produce many practice guidelines as you can see here. Describe a situation where you have used any of these or other guidelines.</p> <p><i>[If they have not used any, then ask them to describe <u>why</u> they haven't used them]</i></p> | <p>Please describe a situation where you wanted (and/or) needed access to these resources? Did you access the resources? Why/why not?</p> <p>When</p> <ul style="list-style-type: none"> ○ During pharmacy training/university? (PO, SO, RM, AM) ○ During intern training? (PO, SO, RM, AM) ○ When providing a new service? (PO, SO, RM, AM) ○ When completing continuing professional development? (PO, SO, RM, AM) ○ When providing patient care? (PO, SO, RM, AM) <p>Why</p> <ul style="list-style-type: none"> ○ Why did you/they use it? (RM, AM, SO) <p>Access and use</p> <ul style="list-style-type: none"> ○ Did you/they find it easy to access? (PsyncC, PO) ○ Did you/they read part of it or all of it? (PsyncC, PO) ○ Did it provide the information that you/they needed? (PsyncC, PO) ○ What worked/was useful? (PsyncC, PO) ○ What didn't work/ was not useful? (PsyncC, PO) ○ How was it accessed? (PsyncC, PO) |
| <p>When thinking about practice guidelines in general or any of the PSA guidelines that we showed you.</p> <p>We would like to know, what influences your use of these resources?</p> | <p>Please describe any barriers or facilitators to using these resources.</p> <p>Capability- Psychological, Physical :</p> <ul style="list-style-type: none"> ○ What do you know about how to use these documents? <i>Describe an example.</i> (PsyncC) ○ What do you think about the content of the documents? <i>Describe an example.</i> (PsyncC, PO) ○ What do you think about structure and or length of these documents? <i>Describe an example.</i> (PsyncC, PO) ○ What skills (if any) do you think are needed to use the documents? (PhysC, PsyncC) <p>Opportunity- Social, Physical:</p> <ul style="list-style-type: none"> ○ What influence do you think time and resources (e.g. money) have on your use of these resources? (PO) ○ What do you think about access to these documents? <i>Describe an example.</i> (PO) ○ What do you think about using these documents in practice? (PO) ○ How do you think these documents can be used when engaging with patients or at point of care? (PO, SO, RM) ○ How do you think others (e.g. patients, prescribers, pharmacists) influence your use of these documents? (SO) ○ How do you think engagement with a professional body influences your use of these guidelines? (SO, PO) <p>Motivation- Automatic, Reflective:</p> <ul style="list-style-type: none"> ○ Please describe how you feel about using/not using these documents? (AM) ○ Do you believe that using these guidelines is/would be a good thing to do? <i>Why/why not?</i> (RM) |
| <p>How do you think these documents could be improved in the future?</p> | <p>How do you think these documents could be improved in the future?</p> <ul style="list-style-type: none"> ○ Please describe what an ideal practice guidance resource would look like. (PO) ○ Please describe how you would use it? (PO, PsyncC) ○ Please describe how you would access them? (PO) ○ Please describe how they would be structured? (PO) ○ Please describe when would you use it? (AM, RM, PO, SO) ○ Please describe why would you use it? (AM, RM, PO, SO) ○ Who do you think should write them? (PO, SO) ○ How do you think they should be advertised and shared? (PsyncC) ○ How detailed do you think they should be (e.g. brief outline or comprehensive with specific examples)? (PO) |

| |
|--|
| Physical capability = PhysC; Psychological capability = PsycC; Social Opportunity = SO; Physical opportunity = PO; Reflective motivation = RM; Automatic motivation = AM |
|--|

53

54 Piloting

55 Two pilot focus groups were conducted (n = 8) for training of the research team, and as a pre-test for the
 56 videoconferencing technology selected to facilitate the discussions and to refine the discussion guide.³⁵ During the
 57 pilot it was decided that an additional researcher was needed to provide technical support to participants and
 58 ensure the moderator could concentrate on the discussions.³⁵ Minor refinements were made to the discussion
 59 guide to ensure questions were clear and use of the videoconferencing software was clear.
 70

71 Focus group facilitation

72 Focus group moderators (DM or LS) conducted focus group discussions. A second researcher (JJ, AR, MH, FF, DB or
 73 EM) was present to take field notes on the discussion and participants responses for further context on the group
 74 dynamic.³⁵ A third researcher (AR, MH, FF, DB or EM) was present to provide technical support to participants when
 75 necessary.³⁵ Participants were asked to log in 10 minutes prior to the scheduled discussion start time, where they
 76 were provided a link to the electronic participant information, demographics and an online consent form to fill out, if
 77 they had not already completed it. Focus groups commenced by confirming completion of consent form and
 78 providing time for participants to ask any clarifying questions, then an outline of the project, the project aims,
 79 explanation of the run time, testing of videoconference technology, rules for discussion and then discussion
 80 questions. The discussions were video and audio recorded.
 81

Deleted: ,

82 Data Analysis

83 The discussions were transcribed verbatim by a transcription service, then verified, and de-identified by one of the
 84 research team (MH, EM, FF or DM). The transcripts were read and re-read for familiarity by each of the researchers
 85 responsible for analysing them (EM, FF or DM). Data fragments, usually sentences or full participant responses were
 86 coded to one or more elements of the COM-B model using the framework method⁶⁰ in duplicate by either DM and
 87 one of FF or EM. After coding two transcripts, the researchers (DM, FF and EM) reviewed their coding and
 88 consistency as a quality assurance measure.⁶¹ The elements and descriptors of each of the COM-B elements were
 89 further refined with additional detail and examples added to promote clarity in interpretation between the
 90 researchers. This was an iterative process and was repeated after two, four then all the transcripts had been
 91 independently coded by at least two researchers (DM and one of EM or FF). At least two researchers (DM and one of
 92 EM or FF) then reviewed the data coded to each COM-B element and independently coded the data fragments, using
 93 an inductive approach to identify subthemes for each element.⁶² The identified subthemes within each element
 94 were also reviewed after two, four and all transcripts has been coded, this was discussed between researchers (DM,
 95 EM, FF) until consensus on those codes, their descriptors and examples were also agreed upon. All coding
 96 disagreements at each stage were resolved through discussion by the analysis team and often included adaptation
 97 to the code descriptors (DD, DM, FF, EM). The final identified subthemes and corresponding data fragments (charted
 98 in a matrix)⁶⁰ were then discussed with experienced behavioural scientist (DD) who sought clarification from the
 99 coding team on the themes descriptors to ensure internal consistency in coding and that subthemes had been
 100 recognised under the appropriate COM-B element. These final themes were presented back to the coding team for
 101 review and were agreed upon. NVivo® (version 12) was used to facilitate coding, theming, and analysis.
 102

103 Data Saturation

104 For this study data saturation was considered to have occurred when no new codes were derived from the inductive
 105 coding of themes within each element of the COM-B framework for at least two consecutive focus groups.

106 Findings

107 Nine focus groups were conducted in August - September 2020. A total of 45 pharmacist participants partook in the
 108 online discussions. This included intern pharmacists to pharmacists with 43 years of experience from community,
 109 hospital and specialty practice settings and metropolitan to remote practice locations. The participants'
 110 demographic data can be viewed in Table 1. Data saturation was reached in the 9th focus group (e.g. no new codes
 111 were generated after the 7th focus group). Discussions on influences on the use of professional practice guidelines
 112 lasted approximately 30-45 minutes.

14 **Table 1-** Demographics of focus group participants

| | Pharmacist focus group type | | | |
|--|-----------------------------|----------------------|---------------------------------|-----------------|
| | Community pharmacists | Hospital pharmacists | Speciality practice pharmacists | Pharmacy owners |
| Total participants, (number of groups) per pharmacist type | 16 (3) | 12 (2) | 8 (1) | 9 (3) |
| Female, n (%) | 12 (75) | 9 (75) | 5 (63) | 6 (67) |
| Years since registration, median (IQR) | 4 (7) | 8 (7) | 28 (27) | 14 (15) |
| Currently working, n (%) | | | | |
| Intern | 2 (13) | 1 (8) | 0 (0) | 0 (0) |
| Registered pharmacist, Full time | 10 (63) | 11 (92) | 7 (88) | 9 (100) |
| Registered pharmacist, Part time | 3 (19) | 0 (0) | 1 (13) | 0 (0) |
| Hours not specified | 1 (6) | 0 (0) | 0 (0) | 0 (0) |
| State/Territory, n (%) | | | | |
| Western Australia | 3 (19) | 0 (0) | 0 (0) | 4 (44) |
| Northern Territory | 1 (6) | 1 (8) | 0 (0) | 0 (0) |
| Queensland | 2 (13) | 0 (0) | 3 (38) | 2 (22) |
| Australian Capital Territory | 2 (13) | 0 (0) | 1 (13) | 0 (0) |
| New South Wales | 4 (25) | 2 (17) | 0 (0) | 0 (0) |
| Victoria | 2 (13) | 4 (33) | 2 (25) | 3 (33) |
| Tasmania | 0 (0) | 1 (8) | 0 (0) | 0 (0) |
| South Australia | 1 (6) | 4 (33) | 2 (25) | 0 (0) |
| State not specified | 1 (6) | 0 (0) | 0 (0) | 0 (0) |
| Rural or remote practice location, n (%) | 3 (19) | 1 (8) | 3 (38) | 3 (33) |

15

16

17


18

19

20

21

The subthemes identified from the COM-B analysis are summarised in Figure 4. Each component of COM-B and its related subtheme(s) are discussed below with illustrative quotes. No data or themes were coded to physical capability or automatic motivation. Quotes are labelled as participant type code and participant number – focus group number. Participant type code: CP = community pharmacist, SP = specialty practice pharmacist, HP = hospital pharmacist, O = Pharmacist Owner.



22
23
24 **Figure 4** - Findings from the thematic analysis mapped to COM-B components

25
26 Discussions and comments from all participant groups commonly started with something along the lines of
27 "I do not use them often but..." and then an example was given by the participant or an explanation as to
28 why.

29
30 COM-B: Psychological Capability

31 *Lack of awareness (Barrier)*

32 Pharmacists expressed that a lack of awareness and knowledge of the existence of these guidelines
33 prevented them from accessing and using them.

34
35 *"And one of the things is the almost marketing or publicity. When those guidelines came out unless*
36 *you are the sort of person that sits and reads every email from start to end, I think a lot of people*
37 *just didn't simply know they were there."* SP4-FG7

38
39 This included a lack of awareness for when practice guidelines were changed or updated.

40
41 *"... The last time I flicked through the APF and saw some of the [S3 guidelines] there's a few more*
42 *that they've sort of snuck in there somewhere at some point, and I've kind of gone that's there, you*
43 *know. So I think for me it's less access and it's more knowing that they're there at all."* CP6-FG2

44
45 COM-B: Social Opportunity

46 *Presence of a patient (Facilitator)*

47 Pharmacists reported being prompted to access and use professional practice guidelines when a patient
48 came in seeking advice for a product or ailment. This was of particular importance when they were unsure
49 how to proceed or wanted reassurance that their actions were going to provide the best possible care for

50 the patient (see *Belief that guidelines can support knowing how to do the right thing in different*
51 *situations*).

52
53 *"I worked a Saturday, I was the only pharmacist on and I had a lady come in for emergency*
54 *contraception and she'd been assaulted. And I just wanted to make sure that I gave her all the*
55 *correct information, who to follow on with, the extra services to offer her. I used [relevant S3*
56 *guidance document] and made sure that I did the right thing as per the guidelines. And it was very*
57 *helpful. It gave me a lot of peace of mind that I'd already done all the right things, that I'd said all*
58 *the right things. I followed up with her, I encouraged her to report it and everything like that."*CP5-
59 FG2

50
51 *Presence of a learner (Facilitator)*

52 Pharmacists who had pharmacy students or intern pharmacists working with them, or those working in a
53 teaching environment would access and use the guidelines to answer the learners' questions and teach
54 appropriate processes. This was to ensure that pharmacists and interns were practising according to
55 legislation and guidelines to provide adequate patient care. Participants noted that this was not usually
56 because they did not know the answer as a practising pharmacist, but more that they wanted to
57 demonstrate how the guidelines could support the learner in practice if they were not sure how to proceed
58 (see *Belief that guidelines can support knowing how to do the right thing in different situations*).

59
60
61 *"I looked [a guideline] up the other day for my intern, you know Neutrafluor, the fluoride*
62 *toothpaste. None of us could remember why its S3. Even after reading the practice guidelines I still*
63 *don't know why its S3. I mean I do, it's the fluoride thing but yeah I often will refer my interns to it*
64 *like if someone wants to get a Chlorsig ointment for their dog and it's like well, that's not why a*
65 *pharmacist can just you know, sell that an S3. Where would you find the answer to that? Not*
66 *having looked there."* O1-FG10

67 COM-B Physical Opportunity

68 *Lack of efficient access (Barrier)*

69 Pharmacists expressed they found the guidelines difficult to locate and access in their current form and
70 agreed that the guidelines should require minimum time to find particularly when needed in patient care
71 situations. Many participants described searching for keywords or descriptions of the guideline in 'Google'
72 and hoping that this brought up what they were looking for.

73
74 *"It's hard to find a website but with Google search if you know the right terms - if you know exactly*
75 *what it is called, you can find it. If you don't know what they are calling that file or that guideline,*
76 *you are pretty well out of luck."* CP2-FG1

77
78 Some participants were aware that the guidelines were able to be access through the PSA's website but
79 suggested that the functionality of this site also limited their ability to locate the guideline they needed.

80
81 *"I know when I was looking for a lot of the practice standards and guidelines when I've been doing*
82 *my work and trying to find them, I had to google them and I had to click all over the blooming*
83 *website until I finally found them and you shouldn't have to do all that digging.."* SP5-FG7

84
85 *Access through a centralised repository (Facilitator)*

86 Participants suggested that a centralised repository of all relevant practice guidelines would aid timely
87 access. Discussions included the repository could be in the form of an application where notifications could
88 be sent when changes were made to the guidelines or that the guidelines could be hosted centrally on a
89 website.

90

31 *"It would be nice to have a repository in the one location where if I just search it up it will just list it*
32 *up there with say the latest version or something like that." HP1-FG4*

33
34 *"If there was an app or something how good would that be?" CP1-FG1*

35
36 *Access promoted through multimodal delivery of guidelines (Facilitator)*

37 Similarly, participants suggested that integrating the guidelines into dispensing software would be a useful
38 way to improve access to and awareness of the guidelines available. Particularly, if the pharmacist was
39 prompted to access them when selecting a related product.

40
41 *"I wonder if inside the dispense software or something there was hyperlinks that you could click on*
42 *to a flowchart while you were dispensing something... so for example, you were putting a morning-*
43 *after pill through...in your dispense software, and...there was a hyperlink and you could go straight*
44 *to a flowchart and [read it and think] oh yeah, I've got to do that.." O1-FG10*

45
46 Use of different delivery modes, such as short videos with links to further information or engaging in
47 "story telling" type awareness campaigns were suggested to facilitate access to guidelines and information,
48 particularly in the time poor environment of pharmacists.

Deleted: "

49
50 *"I think the professional bodies need to engage agencies who are expert at storytelling and get that*
51 *skill into the practice guidelines, so they're more accessible." O3-FG10*

52
53 *Suboptimal content length and layout (Barrier)*

54 Pharmacists acknowledged that the level of detail provided in current guidelines may be necessary when
55 learning how to provide a new service, but that they would be more likely to read a summary.

56
57 *"And almost sometimes having, like with a journal article where there's an abstract at the beginning*
58 *where it's a much more succinct version or a checklist. But you can read more about that if you wish*
59 *to or need to. I mean, some are really good but some are very wordy and it takes you a while to find*
60 *what you want, so sometimes you need to read it two or three times before I've got it straight in my*
61 *head. So having almost a more summarised version of some of them, and you can read onto a more*
62 *detailed version if you need to." O2-FG12*

63
64 Many participants cited flow charts and visual summaries as being useful to enabling them to access the
65 guideline content rapidly, particularly in the case of pharmacists only medicines supply guidelines they
66 would refer to when supply medicines to patients.

67
68 *"...I think that the pharmacist-only medicines guidance documents are really good. Like I actually do*
69 *use them quite a bit just to remember things ...They're just set out really well with that first bit*
70 *where it has like the flowchart, and then it goes into each sort of thing. It's kind of how you would*
71 *approach patients so I think they're really good." CP1-FG2*

72
73 Pharmacists also suggested the guidelines should be online/digital in a searchable format so that they
74 could easily navigate to relevant sections.

75
76 *"I think the search function is the real benefit for electronic guidelines" SP1-FG7*

77
78 *Quality assurance programs as a prompt (Facilitator)*

79 Some pharmacists reported only accessing the guidelines to meet external quality assurance program
80 requirements, such as the Australian Quality Care Pharmacy Program (QCPP). Pharmacists understood they

52 needed to have the guidelines readily accessible to meet these requirements and would seek them out for
53 this reason, but reflected that this did not mean that they would read them.

54
55 *“Just personally I have quite a lot because I’m in the process of getting our other pharmacy ready for*
56 *QCPP and all the changes with QCPP 2020 I have been accessing them a lot recently. But prior to*
57 *that, yeah I’m certainly just as guilty. I’m not going to say that I access things regularly. Generally,*
58 *with policy reviews, which is QCPP related, I would access them.” O2-FG12*

59 COM-B: Reflective Motivation

60 *Belief that guidelines are relevant to current role (Barrier and Facilitator)*

61 Uniquely hospital pharmacists discussed rarely using any of the practice guidelines, citing they lacked
62 relevance to hospital pharmacists’ role and their practice as a reason for not using them. This was the only
63 distinct difference observed in themes between participant groups. Hospital pharmacist participants also
64 reflected that these guidelines would likely be more relevant to those in community pharmacy and if they
65 should transition practice settings suggested this would trigger them to seek them out and review the
66 practice guidelines.

67
68 *“More recently I haven’t referred to them as much and I think that’s to do with the fact that I work*
69 *in a hospital pharmacy and some of these guidelines are more centred around community*
70 *pharmacist roles, in my opinion... I feel like if I was to transition into community pharmacy, that I*
71 *would definitely go back and look at those resources because I think they are quite relevant to the*
72 *everyday activities of the community pharmacist and they’d feel that they would provide me with*
73 *extra knowledge of things that I would need to do or guidelines to follow.” HP2-FG4*

74
75
76 Pharmacists who formally or informally engaged in the role of an educator were prompted to access and
77 use the guidelines, even when they felt they personally knew the information already (see *‘Belief that use*
78 *of guidelines is not routinely required if you are an experienced pharmacist’*). Many suggested that this was
79 the only time they accessed them or when they are of most use.

80
81 *“I use these kinds of guidelines a lot in education, so I volunteer myself to do the codes, the*
82 *practices, the ethics and the PBS dispensing for our intern pharmacists each year, but I also use it*
83 *when I’m educating pharmacy assistants or dispense techs.” HP3-FG4*

84 *Belief that use of guidelines is not routinely required if you are an experienced pharmacist (Barrier)*

85 Many pharmacists felt that the practice guidelines were ingrained in their practice and ‘part of who they
86 were.’ Thus, they did not need to access the documents because they felt they knew the contents, what
87 they are required to do and that they were doing it. This theme clearly related to the perceived level of
88 experience the pharmacist identified themselves to have. With those who considered themselves to be
89 experienced/not needing the guidelines’ and those whom were considered to be ‘inexperienced’ or ‘early
90 career’ being assumed to need them more.

91
92
93 *“With regards to the dispensing practice guidelines, the professional practice standards and code of*
94 *ethics I feel like that’s all ingrained into me so thoroughly at this point that I feel like who I am as a*
95 *pharmacist is part of that if that makes sense. I don’t need to check if I’m still doing the right thing, I*
96 *know that I’m doing the right thing because I’ve been trained for this and I feel that all those things*
97 *have made me the pharmacist that I am but now I don’t need to go and check if I’m still doing the*
98 *right thing.” CP2-FG1*

99
100 Thus, participants reflected that the practice guidelines would likely be of more use to someone who was
101 new to the profession with less experience, such as a recent graduate or intern as they would not have

Deleted:

33 developed this level of knowledge and practice confidence yet. They discussed that they mostly used
34 guidelines when they were initially learning and entering the profession.

35
36 *"I guess if you are a new graduate and you don't have that experience behind you, it's good to have*
37 *guidelines that you can look up and follow but once you've had enough experience out there and*
38 *you've seen the same thing 100 times, generally you can kind of feel your way through it. And as*
39 *FG9-P3 said, you can wing it knowing that what your obligations are as health professionals but also*
40 *being able to be practical about it and getting it done efficiently."* O1-FG9

41
42 The participants that considered themselves experienced also acknowledged that they would access
43 guidelines if they were changed or updated. Although this is completely dependent on them being aware
44 of the change (see 'Lack of awareness').

45
46 *"Or mainly if there's something new, like a down scheduling that is now an S3 medication, that was*
47 *previously prescription only, I might look at something then. Or a new service we're able to provide,*
48 *like with vaccinations... I mean I think the years of doing lots of accreditations and what-not I feel*
49 *reasonably familiar with them but yeah, I certainly wouldn't access them regularly unless I'm*
50 *reviewing something. Or if something's new."* O2-FG12

51
52 *Belief that guidelines can support knowing how to do the right thing in different situations (Facilitator)*
53 Pharmacists reported using the professional practice guidelines when they required information or
54 assurance for the best course of action, in some cases this was to provide best patient care (see 'Presence
55 of a patient' but was often to ensure they met professional obligations such as legislative requirements for
56 compounding a medicine).

57
58 *"I've most recently used the practice standards during my intern year but I've also used the APF a*
59 *little bit when I've been compounding some creams just to double check that I am using the correct*
60 *formula..".* CP4-FG1

61
62 Participants described these occurrences as occasional and triggered by the pharmacist identifying their
63 own knowledge gap while practising and not always in response to a patient presentation.

64
65 *"Or if there's something that I want to double-check you know, something comes up in practice at*
66 *some stage and you're not sure that you're reading or your understanding of what you're supposed*
67 *to be doing there is correct, if it makes mention of a specific part of the thing in a guideline."* CP6-
68 FG2

69
70 This extended to situations where they were unfamiliar with the service that they needed to provide or
71 there had been changes to that service.

72
73 *"So I can understand if all of a sudden new services are available, yes, I would then look at the*
74 *guidelines just to make sure I understand what the protocols are but then after I've used the*
75 *guidelines once I'm never going to look at them again unless there is a new service that I need to*
76 *review. I wouldn't look at them."* O1-FG9

77
78 *Belief that negative consequences may occur if guidelines are not followed (Facilitator)*
79 Consequences of 'not doing the right thing' were discussed by pharmacists and acted as another prompt to
80 use the guidelines. These were discussed in the context of actual consequences for the individual
81 pharmacists, such as losing their registration, or the pharmacy such as losing funding for services and for
82 the patient such as experiencing medicines related harm.

54
55
56
57
58
59
60
61
62
63
64
65

“Especially for things like meds checks, DAAs, supplying all of those things, we have to be aware of the guidelines in order to claim for those professional services so you have to be abiding by those rules in order to get the funding.” CP1-FG1

“...we refer to the guidelines before we make a procedure because if I have like you know a four page or 5-6 page procedure for anything, pharmacists won't read it, it won't happen. And they'll choose bits that they want to do and yeah, cos of where we are logistics we have to be extremely accurate with everything. Cos if I make a mistake here, it goes out to the ...patient, you know that patient could end up in hospital. The nurse might not pick it up. There's lots of things we have to be very careful of.” O2-FG10

Discussion

To the authors' knowledge, this is the first qualitative study to explore barriers and facilitators to pharmacists' use of professional practice guidelines. This study found that use of practice guidelines by practising pharmacists was sporadic and usually prompted by situations arising in practice, involving learners or patients where the pharmacist was unsure how to proceed and may potentially fear what will happen if they do not proceed in a guideline concordant manner. Use of practice guidelines was dependent on the belief that guidelines will support knowing how to proceed in different situations. Furthermore, this use of practice guidelines was also dependent on the individual pharmacist's awareness of the guidelines, their content and understanding of where to find them, facilitated by how easily they can be accessed and navigated when needed. Pharmacists also indicated that they believed practice guidelines were more useful to less experienced pharmacists and for those who identified as experienced pharmacists, routine use was unnecessary. These influences must be considered as part of an interacting system that either results in pharmacists using or not using practice guidelines. How the use of practice guidelines may be preceded by other professional behaviours (e.g. recognising oneself has a knowledge gap and needs support to address it) will also need to be reviewed. Both considerations will be essential in any work to optimise pharmacists' use of professional practice guidelines.

Limited awareness (Psychological Capability) of the guidelines was identified as a barrier in our study. This finding was consistent with previous research. Poor awareness has been suggested as an issue in analogous studies where observed pharmacist practice has deviated from accepted practice guidelines^{16,19,23,28} and educational needs of pharmacists to support practice have been explored.¹⁸ Awareness has also been cited as an issue when reviewing barriers and facilitators for implementation of clinical guidelines and their uptake by prescribers.^{21,63} Improving awareness may increase the motivation of pharmacists to use the guidelines, as knowing that the guidelines exist, along with guideline contents, may influence pharmacists' *perception* of relevance of each guideline to their current role, or *belief* that the guideline may assist them when they do not know how to proceed (Reflective Motivation). If an individual does not know that a guideline exists, has been updated or what information it contains, then they would not be able to use it. Thus, working to improve awareness may be a feasible focus point for intervention, given this may also increase motivation to use the guidelines.

Participants spoke about patients or learners (Social Opportunity) prompting them to access practice guidelines. Pharmacists suggested they accessed the guidelines in these situations because they believed the guideline would support them to provide an appropriate level of care to the patient or to demonstrate to learners how the guideline could provide this support (Reflective Motivation). Furthermore, having a role as an educator (Reflective Motivation) acted as a facilitator in that pharmacists used practice guidelines for the purposes of teaching interns, pharmacy students and/or other pharmacy staff. This has also been identified as a facilitator in previous work where the implementation of medicines supply guidelines was assessed, and participants reported that they mostly used the guideline for educating others.²⁷ Thus, social influences also have the potential to influence the pharmacist's motivation to use the practice guidelines. Interventions focused on this relationship should consider patients and learners as the target and involve consideration of their behaviour in addition to the pharmacist's behaviour (e.g. asking the pharmacist to check their guidelines).

Efficient access to the guidelines and suboptimal content layout and length were identified as barriers (Physical Opportunity) in this study and have been identified in previous studies that observed or described pharmacists' practice,²⁷ use of guidelines,²⁶ identified training needs¹⁸ or reviewed barriers and facilitators to implementation of clinical guidelines by prescribers.^{21,63} Participants were forthcoming with practical solutions that were not dissimilar to those identified in prior research. These included: creating a centralised repository of the guidelines hosted on a website or through a mobile application, pop ups or links to relevant guidelines integrated into dispensing software and thus workflows,²⁷ leveraging the

benefits of technological platforms,^{26,64} such as smart phones^{21,63} and adapting the display of content.^{26,64} These suggestions included providing short summaries of the key points at the start of the document, visualising the content as much as possible in flowcharts or similar and ensuring that the document was well sign posted and searchable. Community pharmacists were prompted to locate practice guidelines when required by upcoming quality assurance program audits (Physical Opportunity), but this didn't necessarily prompt them to read and use the content of the guidance resource. The intent of this requirement of these quality assurances programs may need to be reviewed considering this finding and highlights interventions to promote access do not always ensure use. Improving physical opportunity may also be a target for interventions to increase use of practice guidelines by pharmacists, however, if these interventions were to focus on content and access, they would likely need to be delivered by the guideline developers/owners themselves.

Several influences, pertaining to the Reflective Motivation of pharmacists, with the potential to be targets for behavioural intervention, emerged in this study. Interestingly, some of the identified influences appear to be in direct conflict with others and related to the perceived experience or role of the pharmacist. Some pharmacists indicated they would use the guidelines because they believed negative consequences would occur if they did not. While this was discussed as a powerful motivator when they were early in their career, it was acknowledged that with time and experience, this concern would subside. Thus, this fear of consequences may be a poor target for an intervention if the intention was for the intervention to have a sustained effect over time in a pharmacist's career and suggest interventions may need to be tailored to different career stages. Hospital pharmacists clearly articulated that, in most cases, they did not believe these practice guidelines were relevant to their role and that they were more relevant to community pharmacists (Reflective Motivation). This perception of a 'lack of relevance' was also found to be a common reason for not using practice guidelines in a recent survey study of Australian pharmacists.²⁶ While many of the practice guidelines are community pharmacy centric there are still key resources such as the dispensing guidelines, practice standards, Code of Ethics and governance guidelines that could apply in any practice setting and by thinking this they may be missing out on valuable information or limit their ability to adapt when their scope changes. This may not be an ideal target for intervention development as it would likely need to focus on a subset of the population (e.g. hospital pharmacists) to whom the majority of the guidelines in this study may indeed not be relevant to.

Many pharmacists believed they did not routinely need to use guidelines if they considered themselves to be an experienced or competent pharmacist, suggesting that the guidance provided was 'common sense' and more useful to those early in their career (Reflective Motivation). Contrary to this, many participants also seem to hold the belief that the practice guidelines could support knowing how to do the right thing in different situations and suggested they would review them when they did not know how to proceed in practice when providing patient care or a service. A similar view has been identified in analogous research where prescribers suggested clinical guidelines facilitated confidence in prescribing behaviours and were acknowledged as being useful to standardising care.²¹ While different, both beliefs are likely underpinned by the same thing, the pharmacists' perception of their own competence and ability. In the first, it seems the pharmacist recognise no deficits, whereas in the second, the pharmacist acknowledges they need support and that the guidelines may provide this. In both cases, there is a general risk to practice quality if pharmacists do not recognise that their practice is sub-optimal or that they have a knowledge gap in the first place. Where a pharmacist has made incorrect assumptions about what is acceptable practice or is unable to routinely identify their own knowledge gaps, this sporadic use of the guidelines may become an issue. As discussed in previous studies, this may lead to pharmacists providing a sub-optimal service that damages the trusted relationship that they have with their patients, may breach funding requirements, hinder meeting legal, ethical and professional requirements of registration and thus, professional transgressions.^{11,12} This may be addressed if the use of practice guidelines was routine. Thus, challenging these beliefs may be an effective intervention target to improve use of practice guidelines and indeed

professional behaviour more broadly. However, this should include consideration of the pharmacist's identification of their knowledge gap and how it may be addressed as a target antecedent behaviour.

Recommendations for practice and future research

All stakeholders involved in the writing of practice guidelines should consider the influences identified in this study and how they might address them. Applying the next steps in the Behaviour Change Wheel may assist in this process. These next steps include mapping congruent intervention functions and corresponding behaviour change techniques to the identified influences found in this study, and relevant policy categories to deliver the intervention. It is important to note that in this process, it is often not feasible to target all the identified influences for intervention and that these would need to be prioritised. It may be tempting for guideline writers to focus on addressing the barriers and facilitators identified in this study that pertain to capability and opportunity, as improving awareness and optimising the content of the guidelines would seem well within their remit. Identifying effective strategies for improving awareness of the guidelines, their optimal 'storage' location and what best structure and content looks like should be co-designed with key stakeholders and would also likely require further research. What may be more difficult to address and may need system level changes or input from other stakeholders (the profession, regulators, professional bodies etc.) is influencing the motivational factors identified in this study. Addressing these motivational influences may promote increased use of the practice guidelines, irrespective of how easy they are to access, their current layout, or in the absence of a prompt to do so. Thus, the researchers recommend intervention developers consider all three types of influences as potential key targets for future intervention design and then prioritise them according to likely overall impact on the use of guidelines and the resources available to support intervention implementation. These influences, and the relationships between them, could be considered in review, or development of, new practice guidelines both in Australia and internationally, for pharmacists and other related disciplines. Further work to explore the relative importance of the influences identified so that they can be prioritised as a target for intervention development may be necessary. If the use of a specific resource type is identified as problematic, then an exploration of specific influences for that resource would be recommended, prior to intervention development. The authors strongly advise that any intervention be subject to a systematic development process that is informed by evidence where possible. To provide clarity in what this process may look like, an illustrative example for one influence is included below.

Lack of awareness that the guidelines existed was identified as a barrier that mapped to the COM-B component psychological capability. Intervention functions suggested by the BCW to target capability are 'education' and/or 'training'. For each suggested intervention function the developers should consider the affordability, practicability, effectiveness/cost effectiveness, acceptability, side effects/safety and equity to determine the most appropriate to move forward with. In the case of education and training, due to costs and the sheer number of pharmacists in Australia, training is unlikely to be the most feasible intervention function to select. Additionally, education can be delivered in many different forms. Next steps would involve assessing and selecting Behaviour Change Techniques (BCTs) that are congruent with the education intervention function and considering their appropriateness for the context in which intervention will take place. As an example, the BCT 'information about social and environmental consequences' may be chosen. The resulting intervention may be delivered in the form of a profession wide email campaign, that includes an email delivered by the Pharmacy Board weekly that has a message or headlining case study that features a guideline such as, 'Preventing medication errors through good dispensing practice – Do you know the Dispensing Practice Guidelines?' along with a list or link to all the currently available guidelines that they should be familiar with.

Strengths and limitations

Strengths of this study include the conceptualisation of use of practice guidelines as a behaviour and the use of a systematic theory informed method that facilitated an in-depth exploration of influences that can

be readily operationalised to inform intervention design in the future. Furthermore, the large number and diversity of participants recruited in terms of their geographical practice location, years of experience as a pharmacist and current role was a strength. Facilitation of the focus group discussions online was also a strength, as this allowed the researchers to gain a range of insights and perspectives from geographically diverse participants. Limitations include those common to focus group methodology such as, the views expressed are the participants' own and may have limited generalisability, participants' responses may have been biased by dominant participants' opinions or social desirability and there is a potential for data to be misinterpreted. To mitigate these factors, a demographically and geographically broad range of participants was recruited, and groups were organised according to participants' primary role to reduce response bias where power imbalances may exist (e.g. pharmacist owner vs employee). Furthermore, within the remit of this study all reasonable steps were taken to minimise misinterpretation of data including independent coding of data in duplicate with oversight from a behavioural psychologist with experience using the model. Professional membership status of participants was not collected, therefore differences between the responses of members and non-members could not be ascertained, however participants had the opportunity to raise membership as an influence on guideline use if they desired. Finally, when this study was conducted, Australia was experiencing its second wave of the COVID-19 pandemic (largely localised to one particular state) and, thus, pharmacists as frontline workers were under considerable stress and guidelines for supply of medicines and practice were changing rapidly. This may have affected the results of the study if participants were too absorbed in these changes to consciously reflect and report on them in the focus groups. However, participants were asked about environmental influences and the pandemic was not specifically mentioned.

Conclusions

This study has identified several factors that influence pharmacists' use of professional practice guidelines. Understanding these influences will allow design of behavioural interventions to increase their use. The Behaviour Change Wheel offers clear next steps for this process, including the selection of influences to focus on and mapping of intervention functions to the influences that have an evidence base for working. In this case, awareness, access and content layout will probably need to be improved in the first instance and could be addressed directly by the resource writers. Improving these may also work to improve motivation. However, leveraging influences on motivation may ensure that the use of professional guidelines is embedded in future practice regardless of the other influences. Albeit motivation can be more difficult to target and may require changes to broader practice culture and training that is not directly influenced by resource writers.

References

1. International Pharmaceutical Federation. Good Pharmacy Practice- Joint FIP/WHO Guidelines on GPP: Standards for quality of pharmacy services [Internet]. 2011, [cited Accessed: July 7th 2021]. The Hague, The Netherlands Available from: <https://www.fip.org/file/1476>
2. International Pharmaceutical Federation. FIP Statement of Professional Standards- Code of ethics for pharmacists [Internet]. 2014, [cited Accessed: July 7th 2021]. Available from: www.fip.org/statements
3. Pharmaceutical Society of Australia. National Competency Standards Framework for Pharmacists in Australia (2016) [Internet]. Deakin West, ACT, Australia Pharmaceutical Society of Australia; 2016 [cited 2019 June 3]. Available from: https://my.psa.org.au/servlet/fileField?entityId=ka17F000000cmnyQAA&field=PDF_File_Member_Content_Body_s
4. Pharmaceutical Society of Australia. Professional Practice Standards- Version 5. 2017 [cited Accessed: October 1st 2021]. Deakin West ACT Australia: Pharmaceutical Society of South Australia. Available from: <https://www.psa.org.au/practice-support-industry/professional-practice-standards/>

5. Pharmaceutical Society of Australia. Code of Ethics for Pharmacists. 2017 [cited Accessed: October 1st 2021]. Deakin West, ACT Australia, : Available from: <https://www.psa.org.au/wp-content/uploads/2018/07/PSA-Code-of-Ethics-2017.pdf>
6. Pharmacy Board of Australia. Code of Conduct for Pharmacists. 2014 [cited Accessed: October 1st 2021]. [Internet]. Available from: <https://www.pharmacyboard.gov.au/Codes-Guidelines/Code-of-conduct.aspx>
7. Sansom LN (editor). Australian Pharmaceutical Formulary and Handbook 24th edition. Canberra Pharmaceutical Society of Australia, ; 2018.
8. Pharmaceutical Society of Australia. Guidelines for pharmacists providing dose administration aid services. 2017 (Updated 2020) [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/Guidelines-for-pharmacists-providing-dose-administration-aid-services>
9. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Emergency contraception. Canberra: Pharmaceutical Society of Australia; 2018. Available from: <https://my.psa.org.au/s/article/Emergency-Contraception-S3-Guidance>
10. Pharmaceutical Society of Australia. Dispensing Practice Guidelines. 2019 [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/Dispensing-Practice-Guidelines>
11. Penm J, Chaar BB. Professional transgressions by Australian pharmacists. J Pharm Pract Res. 2009 7 July 2021;39(3):192-197. Available from: 10.1002/j.2055-2335.2009.tb00451.x
12. Sheshtyn P. Failure to maintain standards 2019 [amended 26/04/19; cited 29/04/19]. Australian Journal of Pharmacy Available from: <https://ajp.com.au/news/failure-to-maintain-standards/>
13. Alte D, Weitschies W, Ritter C. Evaluation of consultation in community pharmacies with mystery shoppers. Annals of Pharmacotherapy [Internet]. 2007 [cited 2019 July 2];41(6):1023-30. <https://journals-sagepub-com.access.library.unisa.edu.au/doi/full/10.1345/aph.1H565>
14. Berger K, Eickhoff C, Schulz M. Counselling quality in community pharmacies: implementation of the pseudo customer methodology in Germany. Journal of Clinical Pharmacy & Therapeutics [Internet]. 2005 [cited 2019 July 2];30(1):45-57. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2710.2004.00611.x>
15. Collins JC, Schneider CR, Moles RJ. Emergency contraception supply in Australian pharmacies after the introduction of ulipristal acetate: a mystery shopping mixed-methods study. Contraception. 2018 09;98(3):243-246. Available from: <https://dx.doi.org/10.1016/j.contraception.2018.04.020>
16. Hattingh HL, King MA, Smith NA. An evaluation of the integration of standards and guidelines in community pharmacy practices. Pharmacy World & Science [Internet]. 2009 [cited 2019 July 2];31(5):542-549. Available from: <https://dx.doi.org/10.1007/s11096-009-9309-9>
17. Higgins SJ, Hattingh HI. Requests for emergency contraception in community pharmacy: an evaluation of services provided to mystery patients. Research In Social & Administrative Pharmacy [Internet]. 2013 [cited 2019 July 2];9(1):114-19. Available from: <https://dx.doi.org/10.1016/j.sapharm.2012.03.004>
18. Lai Joyce Chun K, Olsen A, Taing M-W, Clavarino A, Hollingworth S, Dwyer R, et al. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities. Research in Social and Administrative Pharmacy. 2019 2019/08/01;15(8):1014-1020. Available from: <https://doi.org/10.1016/j.sapharm.2019.03.003>
19. Mishriky J, Stupans I, Chan V. Low back pain management – What Australian community pharmacists recommend and how this compares to current clinical guidelines. International Journal of Pharmacy Practice. 2021 [cited 1/20/2022];29(4):336-343. Available from: 10.1093/ijpp/riab022
20. Norris P. Purchasing restricted medicines in New Zealand pharmacies: results from a "mystery shopper" study. Pharmacy World & Science [Internet]. 2002 [cited 2019 July 1];24(4):149-53. <https://link-springer-com.access.library.unisa.edu.au/article/10.1023/A%3A1019506120713>
21. Paksaitė P, Crosskey J, Sula E, West C, Watson M. A systematic review using the Theoretical Domains Framework to identify barriers and facilitators to the adoption of prescribing guidelines. Int J Pharm Pract. 2021;29(1):3-11. Available from: 10.1111/ijpp.12654

22. Puspitasari HP, Aslani P, Krass I. A review of counseling practices on prescription medicines in community pharmacies. *Research In Social & Administrative Pharmacy* [Internet]. 2009 [cited 2019 July 2];5(3):197-210. Available from: <https://dx.doi.org/10.1016/j.sapharm.2008.08.006>
23. Puspitasari HP, Aslani P, Krass I. Australian community pharmacists' awareness and practice in supporting secondary prevention of cardiovascular disease. *Int J Clin Pharm*. 2013;35(6):1218-1228. Available from: 10.1007/s11096-013-9854-0
24. Rutter PM, Horsley E, Brown DT. Evaluation of Community Pharmacists' Recommendations to Standardized Patient Scenarios. *Annals of Pharmacotherapy* [Internet]. 2004 [cited 2019 July 1];38(6):1080-1085. Available from: 10.1345/aph.1D519
25. Schneider C, Gudka S, Fleischer L, Clifford R. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. *Pharmacy Practice* [Internet]. 2013 [cited 2019 June 20];11(3):127-131. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809138/pdf/pharmpract-11-127.pdf>
26. Mill D, Johnson JL, Lee K, Salter SM, D'Lima D, Seubert L, et al. Use of professional practice guidance resources in pharmacy: a cross-sectional nationwide survey of pharmacists, intern pharmacists, and pharmacy students. *Journal of Pharmaceutical Policy and Practice*. 2021;14(1):1-19. Available from: 10.1186/s40545-021-00395-8
27. Watkins K, Fisher C, Misaghian J, Schneider CR, Clifford R. A qualitative evaluation of the implementation of guidelines and a support tool for asthma management in primary care. *Asthma Research and Practice*. 2016 2016/05/04;2(1):8. Available from: 10.1186/s40733-016-0023-9
28. Chaar B, Brien JA, Krass I. Professional ethics in pharmacy: The Australian experience. *International Journal of Pharmacy Practice*. 2005;13(3):195-204. Available from: 10.1211/ijpp.13.3.0005
29. Michie S, Atkins L, West R. *The Behaviour Change Wheel: A Guide to Designing Interventions*. 1st ed. Great Britain Silverback Publishing 2014.
30. Michie S, Van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. *Impl Sci* [Internet]. 2011 April 23 [cited 2019 July 2];6(1). Available from: 10.1186/1748-5908-6-42
31. Korenvain C, MacKeigan LD, Dainty KN, Guilcher SJT, McCarthy LM. Exploring deprescribing opportunities for community pharmacists using the Behaviour Change Wheel. *Research in Social and Administrative Pharmacy*. 2020 2020/12/01;16(12):1746-1753. Available from: <https://doi.org/10.1016/j.sapharm.2020.01.019>
32. Nielsen S, Olsen A. Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia. *International Journal of Drug Policy*. 2021 2021/04/01;90:103061. Available from: <https://doi.org/10.1016/j.drugpo.2020.103061>
33. Seubert LJ, Kerry W, Laetitia H, Watson MC, Clifford RM. A Theory Based Intervention to Enhance Information Exchange during Over-The-Counter Consultations in Community Pharmacy: A Feasibility Study. *Pharmacy* [Internet]. 2019 [cited 2019 July 2];7(2). Available from: 10.3390/pharmacy7020073
34. Pharmacy Board of Australia. Guidelines on Practice Specific Issues – Guideline 1 (List of reference texts for Pharmacists) September 2015 [cited Accessed: August 18th 2022]. Available from: <https://www.pharmacyboard.gov.au/codes-guidelines.aspx>
35. Halliday M, Mill D, Johnson J, Lee K. Let's talk virtual! Online focus group facilitation for the modern researcher. *Research in Social and Administrative Pharmacy*. 2021:1-6. Available from: 10.1016/j.sapharm.2021.02.003
36. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349-357. Available from: 10.1093/intqhc/mzm042
37. Pharmaceutical Society of Australia. *My Health Record Guidelines for Pharmacists*. 2019 [cited Accessed: October 1st 2021]. Available from: <https://www.psa.org.au/wp-content/uploads/2019/09/MHR-Guidelines-for-Pharmacists.pdf>

38. Pharmaceutical Society of Australia. Clinical Governance Principles for Pharmacy Services. 2018 [cited Accessed: October 1st 2021]. Available from: https://www.psa.org.au/wp-content/uploads/2019/05/PSAClinicalGovernancePrinciples2018_FINAL.pdf
39. Pharmaceutical Society of Australia. Guide to providing pharmacy services to Aboriginal and Torres Strait Islander people. 2014 [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/Providing-Pharmacy-Services-to-Aboriginal-and-Torres-Strait-Islander-People>
40. Pharmaceutical Society of Australia. Guidelines for pharmacists providing staged supply services. 2017 (Updated 2019) [cited Accessed: October 1st 2021]. Available from: https://my.psa.org.au/servlet/fileField?entityId=ka10o0000001DaSAAU&field=PDF_File_Member_Content_Body_s
41. Pharmaceutical Society of Australia. Guidelines for pharmacists providing MedsCheck and Diabetes MedsCheck services. 2017 (Updated 2019), [cited Accessed: October 1st 2019]. Available from: <https://my.psa.org.au/s/article/Guidelines-for-pharmacists-providing-MedsCheck-and-Diabetes-MedsCheck-services>
42. Pharmaceutical Society of Australia. Practice guidelines for the provision of immunisation services within pharmacy. 2020 [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/immunisation-guidelines>
43. Pharmaceutical Society of Australia. Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists. 2018 (Updated 2020) [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/Continued-dispensing-guidelines>
44. Pharmaceutical Society of Australia. Guidelines for Quality Use of Medicines (QUM) services. 2020 [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/guidelines-for-qum-services>
45. Pharmaceutical Society of Australia. Guidelines for pharmacists providing Home Medicines Review (HMR) services. 2011 [cited Accessed: October 1st 2021]. Available from: <https://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-Guidelines-for-Providing-Home-Medicines-Review-HMR-Services.pdf>
46. Pharmaceutical Society of Australia. Guidelines for pharmacists providing Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) services. 2011 (Updated 2018) [Available from: <https://www.ppaonline.com.au/wp-content/uploads/2019/01/PSA-RMMR-and-QUM-Guidelines.pdf>
47. Pharmaceutical Society of Australia. Guidelines for comprehensive medication management reviews. 2020 [cited Accessed: October 1st 2021]. Available from: <https://my.psa.org.au/s/article/guidelines-for-comprehensive-mmr>
48. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Chloramphenicol for ophthalmic use. Canberra: Pharmaceutical Society of Australia; 2017. Available from: <https://my.psa.org.au/s/article/Chloramphenicol-S3-guidance-document>
49. Pharmaceutical Society of Australia. Guidance for provision of Pharmacist Only medicine Naloxone. Canberra: Pharmaceutical Society of Australia; 2019. Available from: <https://my.psa.org.au/s/article/Naloxone-S3-guidance-document>
50. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Orlistat. Canberra: Pharmaceutical Society of Australia; 2017. Available from: <https://my.psa.org.au/s/article/Orlistat-S3-guidance-document>
51. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Prochlorperazine. Canberra: Pharmaceutical Society of Australia; 2017.
52. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Proton pump inhibitors. Canberra: Pharmaceutical Society of Australia; 2017. Available from: <https://my.psa.org.au/s/article/Proton-pump-inhibitors-S3-guidance-document>

53. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Short-acting beta2 agonists (salbutamol and terbutaline). Canberra: Pharmaceutical Society of Australia; 2017. Available from: <https://my.psa.org.au/s/article/Short-acting-beta-agonists-S3-guidance-document>
54. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Famciclovir. Canberra: Pharmaceutical Society of Australia; 2017. Available from: <https://my.psa.org.au/s/article/Famciclovir-S3-guidance-document>
55. Pharmaceutical Society of Australia. Guidance for provision of Pharmacist Only medicine Adrenaline (epinephrine). Canberra: Pharmaceutical Society of Australia; 2019. Available from: <https://my.psa.org.au/s/article/Adrenaline-epinephrine-guidance-document>
56. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Astodimer sodium. Canberra: Pharmaceutical Society of Australia; 2019. Available from: <https://my.psa.org.au/s/article/Astodimer-S3-guidance-document>
57. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Glucagon. Canberra: Pharmaceutical Society of Australia; 2019. Available from: <https://my.psa.org.au/s/article/Glucagon-S3-guidance-document>
58. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine High-concentration fluoride toothpaste. Canberra: Pharmaceutical Society of Australia 2019. Available from: <https://my.psa.org.au/s/article/High-concentration-fluoride>
59. Pharmaceutical Society of Australia. Guidance for provision of a Pharmacist Only medicine Nitrates. Canberra: Pharmaceutical Society of Australia; 2019. Available from: <https://my.psa.org.au/s/article/Nitrates-S3-guidance-document>
60. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol.* 2013;13(1):117-117. Available from: 10.1186/1471-2288-13-117
61. Amin MEK, Nørgaard LS, Cavaco AM, Witry MJ, Hillman L, Cernasev A, et al. Establishing trustworthiness and authenticity in qualitative pharmacy research. *Research in Social and Administrative Pharmacy.* 2020 2020/10/01/;16(10):1472-1482. Available from: <https://doi.org/10.1016/j.sapharm.2020.02.005>
62. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative research in psychology.* 2006;3(2):77-101. Available from: 10.1191/1478088706qp063oa
63. Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and Strategies in Guideline Implementation- A Scoping Review. *Healthcare (Basel).* 2016;4(3):36. Available from: 10.3390/healthcare4030036
64. Mill D, Page A, Johnson J, Lee K, Salter SM, Seubert L, et al. Do pharmacy practice standards effectively describe behaviour? Reviewing practice standards using a behavioural specificity framework. *BMC Health Serv Res.* 2022;22(1):71-71. Available from: 10.1186/s12913-021-07358-4

Appendices

Appendix 1 - Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist³⁶

| No | Item | Guide questions/description | Detail reported or section of manuscript reported in |
|--|--------------------------|---|---|
| Domain 1: Research team and reflexivity | | | |
| Personal Characteristics | | | |
| 1. | Interviewer/facilitator | Which author/s conducted the interview or focus group? | LS and DM were the moderators – see methods – focus group facilitation. |
| 2. | Credentials | What were the researcher's credentials? <i>E.g. PhD, MD</i> | LS - BPharm PhD DM – BPharm (Hons) |
| 3. | Occupation | What was their occupation at the time of the study? | LS head of pharmacy program at UWA – see author affiliations DM – pharmacist and PhD candidate at UWA – see author affiliations |
| 4. | Gender | Was the researcher male or female? | - |
| 5. | Experience and training | What experience or training did the researcher have? | See Methods - Research team and Researcher training |
| Relationship with participants | | | |
| 6. | Relationship established | Was a relationship established prior to study commencement? | Some participants may have known researchers and facilitators given participants were also registered pharmacist and recruited through professional networks. |

| No | Item | Guide questions/description | Detail reported or section of manuscript reported in |
|-----------------------------------|--|---|--|
| 7. | Participant knowledge of the interviewer | What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i> | Occupation, reasons for research and source of funding |
| 8. | Interviewer characteristics | What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons and interests in the research topic</i> | Occupation |
| Domain 2: study design | | | |
| Theoretical framework | | | |
| 9. | Methodological orientation and Theory | What methodological orientation was stated to underpin the study? <i>e.g. grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i> | Descriptive qualitative focus groups – see methods |
| Participant selection | | | |
| 10. | Sampling | How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i> | Purposive – see Methods - Sample |
| 11. | Method of approach | How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i> | Online via email or social media advertisement – see Methods – Recruitment |
| 12. | Sample size | How many participants were in the study? | 45 – See Findings |
| 13. | Non-participation | How many people refused to participate or dropped out? Reasons? | Not determined |
| Setting | | | |

| No | Item | Guide questions/description | Detail reported or section of manuscript reported in |
|-----------------|------------------------------|--|---|
| 14. | Setting of data collection | Where was the data collected? <i>e.g. home, clinic, workplace</i> | Online via videoconferencing platform – see Methods – Focus group facilitation |
| 15. | Presence of non-participants | Was anyone else present besides the participants and researchers? | Yes and observer and a technical support officer – See Methods – Focus group facilitation |
| 16. | Description of sample | What are the important characteristics of the sample? <i>e.g. demographic data, date</i> | See reported demographics in Table 1 |
| Data collection | | | |
| 17. | Interview guide | Were questions, prompts, guides provided by the authors? Was it pilot tested? | Yes – See Methods – Piloting and Discussion guide |
| 18. | Repeat interviews | Were repeat interviews carried out? If yes, how many? | No. |
| 19. | Audio/visual recording | Did the research use audio or visual recording to collect the data? | Both were recorded, only audio was used for analysis – see Methods – Focus group facilitation |
| 20. | Field notes | Were field notes made during and/or after the interview or focus group? | Yes – see Methods Focus group facilitation |
| 21. | Duration | What was the duration of the interviews or focus group? | 30-45 minutes – see Findings |
| 22. | Data saturation | Was data saturation discussed? | Yes – see results and methods |
| 23. | Transcripts returned | Were transcripts returned to participants for comment and/or correction? | No. |